AstraZeneca and Pfizer: What are the side effects of Australia’s vaccines? People under 55, women and those previously infected with COVID-19 are more likely to report side effects after receiving either vaccine, according to new research.
GPs with AstraZeneca stockpile turn attention to vaccinating over-50s Patient concerns around the AstraZeneca vaccine have seen a decline in interest in some practices, prompting GPs to bring forward the new rollout strategy’s commencement date.
Benefits of AstraZeneca overwhelmingly high despite increased clotting risk New European research has found the risk of a rare blood clotting syndrome associated with the vaccine is double what has been previously reported.
Growing number of Australians reject COVID vaccination Vaccine hesitancy has soared since recommendations shifted from AstraZeneca to Pfizer for under-50s.
Telehealth extended but details remain limited The RACGP has cautiously welcomed the six month extension but is still waiting to confirm the policy’s final details.
Are blood clots a concern with mRNA vaccines? An investigation into Australia’s first case of blood clotting after the Pfizer vaccine has yet to confirm a link.
GPs set to receive more AstraZeneca doses in fast-tracked rollout The shift means people over 50 will have access to COVID vaccines from GP respiratory clinics from 3 May, and general practices from 17 May.
Funding for in-home COVID vaccine assessments ‘inadequate’ GPs have questioned the lack of a dedicated MBS item number for housebound patients.
Blood clot case under investigation following Pfizer vaccine The news comes as Australia moves to establish local mRNA manufacturing capacity and experts call for current Pfizer supplies to be redirected to younger cohorts.
Major reset to vaccination program: What will it mean for GPs? GPs have welcomed the National Cabinet’s proposal to revise the vaccine roadmap but say supply issues must be addressed before any major changes are made.